France’s Sanofi predicts “slightly negative” vaccine sales this year due to U.S. policy changes under President Trump. CEO Paul Hudson notes challenges in the sector, particularly with pediatric vaccines, amid debates and anti-vaccine activism. The company aims for high-single-digit overall sales growth by 2026 despite this setback.

Sanofi faces the challenge of replacing blockbuster drug Dupixent once it loses key patents in the early 2030s. Chief Financial Officer François-Xavier Roger admits the loss will be significant and difficult to offset. The company plans to cushion the impact through existing products, new launches, and strategic acquisitions.

Despite the looming patent expiration of Dupixent, Sanofi remains cautious about acquisitions. The company aims to strategically acquire assets that make sense for long-term growth rather than spending for the sake of spending. Their recent $9.5 billion acquisition of Blueprint Medicines added Ayvakit, a drug for a rare blood disorder, to their portfolio.

Read more at Yahoo Finance: Sanofi vaccine sales face headwinds from US policy shifts